Protein aggregates and dementia: Is there a common toxicity?

Journal of Neurology Neurosurgery and Psychiatry

Volumn 72, Issue 2, 2002, Pages 152-161

  Lovestone, S ^a   McLoughlin, D M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GAMMA SECRETASE; HUNTINGTIN; POLYGLUTAMINE; PRESENILIN 1; PRESENILIN 2; PRION PROTEIN; REELIN; SYNUCLEIN; TAU PROTEIN;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DEMENTIA; LEWY BODY; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID; BRAIN; EXTRACELLULAR SPACE; HUMANS; INCLUSION BODIES; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PRIONS; PROTEINS; SYNUCLEINS; TAU PROTEINS;

EID: 0036157895     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.72.2.152     Document Type: Review

References (125)

1. Translating cell biology into therapeutic advances in Alzheimer's disease
2. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
3. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
4. The cause of neuronal degeneration in Alzheimer's disease
5. Mutant genes in familial Alzheimer's disease and transgenic models
6. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity
7. Neuropathological stageing of Alzheimer-related changes
8. Transgenic mouse models of Alzheimer's disease
9. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
10. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
11. Identification of a novel aspartic protease (Asp 2) as β-secretase
12. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
13. Purification and cloning of amyloid precursor protein β-secretase from human brain
14. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
15. BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21
16. Expression analysis of BACE2 in brain and peripheral tissues
17. BACE2, a β-secretase homolog, cleaves at the β-site and within the amyloid-β region of the amyloid-β precursor protein
18. Presenillns: Molecular switches between proteolysis and signal transduction
19. Presenilin 1 is required for Notch 1 Dll1 expression in the paraxial mesoderm
20. Skeletal and CNS defects in presenilin-1-deficient mice
21. Notch 1 is required for the coordinate segmentation of somites
22. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
23. Effects of PS1 deficiency on membrane protein trafficking in neurons
24. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1
25. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
26. Presenilin-1 differentially facilitates endoproteolysis of the γ-amyloid precursor protein and notch
27. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1
28. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
29. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state
30. ApoE genotype predicts when, not whether, one is predisposed to develop Alzheimer disease
31. Lack of apolipoprotein E dramatically reduces amyloid β. peptide deposition
32. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
33. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease
34. Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype
35. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer disease
36. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
37. Direct binding of reelin to VLDL receptor and apoF receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation
38. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein
39. Fe65 and the protein network centered around the cytosolic domain of the Alzheimer's β-amyloid precursor protein
40. Regulation of β-amyloid secretion by FE65, an amyloid protein precursor-binding protein
41. hFE65L influences amyloid precursor protein maturation and secretion
42. The X11α protein slows cellular amyloid precursor protein processing and reduces Aβ40 and Aβ42 secretion
43. X11 inleraction with β-amyloid precursor protein modulates its cellular stabilization and reduces amyloid β-protein secretion
44. The Fe65 and XII families of proteins: Proteins that interact with the Alzheimer's disease amyloid precursor protein
45. Interaction of a neuron-specific protein containing PDZ domains with Alzheimer's amyloid precursor protein
46. X11α and X11β interact with presenilin-1 via their PDZ domains
47. Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP): Evidence that LRP contributes to the pathogenesis of Alzheimer's disease
48. A full genome scan for late onset Alzheimer's disease
49. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
50. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees
51. Susceptibility locus for Alzhelmer's disease on chromosome 10
52. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q
53. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme
54. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
55. Microtubule-associated protein tau (tau) is a major antigenic componenl of paired helical filaments in Alzheimer disease
56. Tau protein pathology in neurodegenerative diseases
57. Regulation of tau phosphorylation in Alzheimer's disease
58. The phosphorylation of tau: A critical stage in neurodevelopmental and neurodegenerative processes
59. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
60. Untangling tau-related dementia
61. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease
62. Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits
63. Tau gene mutation K257t causes a tauopathy similar to Pick's disease
64. Association of an extended haplotype in the tau gene with progressive supranudear palsy
65. 5′ Splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10
66. Tau proteins with FTDP.17 mutations have a reduced ability to promote microtubule assembly
67. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
68. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation
69. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations
70. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
71. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
72. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
73. Staging of Alzheimer's disease-related neurofibrillary changes
74. Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: The effects on organisation and stability of microtubules
75. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease
76. Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease
77. Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans - Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation
78. Synuclein proteins and Alzheimer's disease
79. Synelfin regulation during the critical period for song learning in normal and isolated juvenile zebra finches
80. Alpha-synuclein in Lewy bodies
81. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
82. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with lewy bodies
83. Mutation in the α-synuclein gene identified in families with Parkinson's disease
84. Multiple system atrophy: A sporadic synucleinopathy
85. A drosophila model of Parkinson's disease
86. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
87. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons
88. Expression pattern of synucleins (non-Aβ component of Alzheimer's disease amyloid precursor protein α-synuclein) during murine brain development
89. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
90. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onsel Parkinson disease
91. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease
92. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation
93. α-Synuclein fibrillogenesis is nucleation-dependent: Implications for the pathogenesis of Parkinson's disease
94. Degradation of α-synuclein by proteasome
95. Cellular biology of prion diseases
96. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent
97. The cellular prion protein binds copper in vivo
98. Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein
99. Prion protein genes and prion diseases: Studies in transgenic mice
100. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment
101. Sc-like prion protein peptide inhibits the function of cellular prion protein
102. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
103. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
104. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
105. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
106. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
107. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
108. Glutamine repeats and neurodegenerative diseases: Molecular aspects
109. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture
110. The influence of huntingtin protein size on nuclear localization and cellular toxicity
111. A cellular model that recapitulates major pathogenic steps of Huntington's disease
112. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease
113. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
114. Ultrastructura] localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice
115. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity
116. Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: Applying to quantification of protein components of the aggregates
117. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy
118. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity
119. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils
120. Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticold receptor
121. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells
122. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
123. Impairment of the ubiquitin-proteosome system by protein aggrgegtaion
124. Immunization with amyloid-β attenuates Alzheimer disease like pathology in the PDAPP mouse
125. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease